Skip to content

Philippe Courtet

9 papers in the library · 212 citations · publishing 2020-2026

Papers

Sort Most recent Most cited

Intranasal Esketamine Versus Other Pharmacological Strategies in Treatment-Resistant Depression with High Suicide Risk: A Six-Month Naturalistic Study.

Clinics and practice June 12, 2026 Ana María De Granda-Beltrán, Alejandro Porras-Segovia, Daniel Núñez-arias et al.

Background: Treatment-resistant depression (TRD) poses a major clinical challenge, particularly when accompanied by suicidal behavior. Intranasal esketamine has demonstrated rapid antidepressant effects in TRD, but real-world comparative evidence remains limited. Methods: We conducted a six-month naturalistic prospective cohort study in two Spanish mental health centers, including 62 TRD...

One dose of Psilocybin modulates Brain Activity among Depressive patients : Preliminary Neuroimaging Results from the PSILODAC Study

European Psychiatry June 1, 2026 M. Pastre, F. Pereira, T. Gibert et al.

Introduction Treatment-resistant depression (TRD) remains a major clinical challenge, with limited efficacy of available therapies. Psilocybin, a serotonergic psychedelic, has shown promising antidepressant effects. As recent studies have shown altered default mode network activity following psilocybin administration, further neuroimaging research in clinical populations is needed to clarify...

Esketamine use in real-world clinical practice in patients with treatment-resistant depression.

European Psychiatry August 26, 2025 Ismaël Conejero, Raquel Alvarez García, Alejandro Porras-Segovia et al. 2 citations

Esketamine has been shown to produce a major antidepressant response in patients with treatment-resistant depression (TRD). We evaluated the factors associated with achieving remission in these individuals. The study was carried out across four psychiatry departments in Madrid, Spain. Patients aged over 18 years were included if they received esketamine as an augmentation treatment for TRD....

DOI: 10.1192/j.eurpsy.2025.10096 (opens in new tab) Full text (opens in new tab) Esketamine Augmentation treatment Naturalistic study Treatment resistant depression

[Suicidal ideation and behaviors: a transdiagnostic dimension for precision psychiatry].

Medecine sciences : M/S May 1, 2025 Aiste Lengvenyte, Emilie Olié, Marion Leboyer et al.

Suicidal thoughts and behaviors represent a transdiagnostic dimension independent of traditional psychiatric diagnoses. This specificity is supported by genetic studies, biomarkers, and preclinical research on endophenotypes associated with suicidal behaviors, such as impulsivity, anhedonia, and hopelessness. Clear mechanisms involving inflammation, the stress response, the serotonergic system,...

DOI: 10.1051/medsci/2025066 (opens in new tab) Full text (opens in new tab) Suicide-research Neurobiology-mental-health Biomarkers-medicine Personalized-psychiatry +1

French Translation and Validation of the Ontological Addiction Scale (OAS).

International Journal of Environmental Research and Public Health March 27, 2025 Déborah Ducasse, Martin Leurent, Marie-Christine Picot et al. 1 citation

According to ontological addiction theory, the root cause of mental suffering is a dysfunctional conceptualisation of the self. Typically, an individual with such a flawed self-concept deems themselves to be intrinsically separate from their surroundings, with their beliefs, choices and behaviours structured in order to reinforce their sense of an independently existing self. The Ontological...

DOI: 10.3390/ijerph22040511 (opens in new tab) Full text (opens in new tab) Buddhist-derived practices Ontological addiction scale Scale validation

[How can ketamine be used to manage suicidal risk?].

Biologie aujourd'hui 2023 Emilie Olié, Aiste Lengvenyte, Philippe Courtet

In France, suicidal behaviors remain a major public health issue. Depressed patients with suicidal ideation have more severe depressive symptoms, a more unfavorable disease course, and a greater number of suicide attempts than patients without suicidal ideation. Unfortunately, conventional antidepressants tend to be less effective in patients with suicidal tendencies than in those without....

DOI: 10.1051/jbio/2023029 (opens in new tab) Full text (opens in new tab) Ketamine Conduites suicidaires Kétamine Suicidal behavior +1

Ketamine for the acute treatment of severe suicidal ideation: double blind, randomised placebo controlled trial

British medical journal February 2, 2022 M. Abbar, C. Demattei, Wissam El-Hage et al. 172 citations

Abstract Objective To confirm the rapid onset anti-suicidal benefits of ketamine in the short term and at six weeks, overall and according to diagnostic group. Design Prospective, double blind, superiority, randomised placebo controlled trial. Setting Seven French teaching hospitals between 13 April 2015 and 12 March 2019. Eligibility criteria for participants Aged 18 or older with current...

Psilocybin, a Naturally Occurring Indoleamine Compound, Could Be Useful to Prevent Suicidal Behaviors

Pharmaceuticals November 24, 2021 Robertas Strumila, Bénédicte Nobile, Laura Korsakova et al. 35 citations

The available interventions for people who are at risk of suicide have limited efficacy. Recently, research on new mental health treatments has started to consider psychedelic compounds, particularly psilocybin, a molecule with a few thousand years of history of use in human societies. The possible effects of psilocybin on suicidal ideation and behaviors have not been specifically studied yet;...

DOI: 10.3390/ph14121213 (opens in new tab) Psilocybin Suicidal ideation Hallucinogen Clinical psychology +3

Commentary: Psychedelic Psychiatry's Brave New World.

Frontiers in Psychiatry November 26, 2020 Bénédicte Nobile, Emilie Olié, Philippe Courtet 2 citations

In their recent article entitled “Psychedelic Psychiatry's Brave New World,” Nutt et al. (1) wrote that new research on psychedelic drugs, especially psilocybin, has highlighted their potential for psychiatric disorder management. In the past decade, many studies focused on psilocybin effects on mood disorders (2) showing that it can significantly improve depressive symptomatology for weeks and...

DOI: 10.3389/fpsyt.2020.594077 (opens in new tab) Full text (opens in new tab) Psychedelic therapy Mental health treatment Clinical integration Innovative psychiatry